![](https://library.celltelligence.com/wp-content/uploads/2021/10/Gilead_Announcement.png)
$0
FDA Approves an Updated Label for Yescarta to Include Prophylactic Corticosteroids Use
On Monday, January 31, Gilead (Kite) announced (press release) that the FDA has approved Yescarta’s (CD19 CAR-T) updated prescribing information to include the use of prophylactic corticosteroids across all approved indications. Of note, the label update is based on results from Cohort 6 of the Ph1/2 ZUMA-1 trial in r/r DLBCL. Below, Celltelligence provides insights on Yescarta’s updated US label, while discussing how it could facilitate Yescarta’s administration in the outpatient setting.